Comparison of sitagliptin and glimepiride in patients with type 2 diabetes mellitus

Comparison of sitagliptin and glimepiride in patients with type 2 diabetes mellitus - Comparison of sitagliptin and glimepiride in patients with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017566

Enrollment

200

Registered

2015-05-18

Start date

2010-05-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

sitagliptin glimepiride

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes inadequately controlled with following therapies (HbA1c 6.9~10.4%) 1) diet and exercise therapy 2) treated with glinides or biguanides or pioglitazone monotherapy 3) treated with glinides and biguanides or pioglitazone (dual therapy)

Exclusion criteria

Exclusion criteria: 1) kidney dysfunction (serum creatinine > 1.5 mg/dl in men, >1.3 mg/dl in women, or nephrotic syndrome) 2) heart failure, stroke 3) liver dysfunction (serum AST and/or ALT >100mU/ml or liver cirrhosis) 4) respiratory failure (needing oxygen therapy) 5) pregnant women 6) treated with sulfonyureas or alpha-glucosidase inhibitors 7) ketosis, diabetic coma, type 1 diabetes mellitus, severe infection 8) dementia 9) other inadequate patients

Design outcomes

Primary

Measure	Time frame
HbA1c, body weight, hypoglycemia	—

Secondary

Measure	Time frame
glycoalbumin, 1, 5-anhydroglucitol, blood pressure, lipids, insulin, proinsulin, adiponectin, leptin, CRP, bone metabolic markers, durability, safety	—

Countries

Japan

Contacts

Public ContactShoichiro Nagasaka

Jichi Medical University Division of Endocrinology and Metabolism

sngsk@jichi.ac.jp81-285-58-7355

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026